Protease activity-based nanobiosensors for early detection of pancreatic cancer
Main Article Content
Abstract
Five-year survival rate for pancreatic cancer patients has increased to 12.8% after the initial diagnosis, still making it one of the deadliest cancer types. This disease is known as the “silent killer” because early detection is challenging due to the location of the pancreas in the body and the nonspecific clinical symptoms. The Bossmann group has developed ultrasensitive nanobiosensors for protease/arginase detection comprised of Fe/Fe3O4 nanoparticles, cyanine 5.5, and designer peptide sequences linked to TCPP. Initial data obtained from both gene expression analysis and protease/arginase activity detection in serum indicated the feasibility of early pancreatic cancer detection. Several matrix metalloproteinases (MMPs, -1, -3, and -9), cathepsins (CTS) B and E, neutrophil elastase, and urokinase plaminogen activator (uPA) have been identified as candidates for proximal biomarkers. In this study, we have confirmed our initial results from 2018 performing serum sample analysis assays using a larger group sample size (n=159), which included localized (n=33) and metastatic pancreatic cancer (n=50), pancreatitis (n=26), and an age-matched healthy control group (n=50). The data obtained from the eight nanobiosensors capable of ultrasensitive protease and arginase activity measurements were analyzed by means of an optimized information fusion-based hierarchical decision structure. This permits the modeling of early-stage detection of pancreatic cancer as a multi-class classification problem. The most striking result is that this methodology permits the detection of localized pancreatic cancers from serum analyses with around 96% accuracy.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
https://doi.org:10.1158/0008-5472.Can-14-0155
2. https://seer.cancer.gov/statfacts/html/pancreas.html.
3. https://www.nfcr.org/cancer-types/pancreatic-cancer/.
4. Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet 395, 2008-2020 (2020). https://doi.org:10.1016/s0140-6736(20)30974-0
5. https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html.
6. Bossmann, S. H. in Biomaterials for Cancer Therapeutics - Evolution and Innovation Vol. 2 (ed Kinam Park) Ch. 9, 233-260 (Elsevier, 2020).
7. https://www.cancer.gov/news-events/cancer-currents-blog/2017/liquid-biopsy-detects-treats-cancer.
8. Snow, A., Chen, D. & Lang, J. E. The current status of the clinical utility of liquid biopsies in cancer. Expert Rev Mol Diagn 19, 1031-1041 (2019). https://doi.org:10.1080/14737159.2019.1664290
9. Di Capua, D., Bracken-Clarke, D., Ronan, K., Baird, A. M. & Finn, S. The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments. Cancers (Basel) 13 (2021). https://doi.org:10.3390/cancers13163923
10. Tay, T. K. Y. & Tan, P. H. Liquid Biopsy in Breast Cancer: A Focused Review. Arch Pathol Lab Med 145, 678-686 (2021). https://doi.org:10.5858/arpa.2019-0559-RA
11. Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol 18, 297-312 (2021). https://doi.org:10.1038/s41571-020-00457-x
12. Heredia-Soto, V., Rodríguez-Salas, N. & Feliu, J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 13 (2021). https://doi.org:10.3390/cancers13081986
13. Toledano-Fonseca, M. et al. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. Cancers (Basel) 12 (2020). https://doi.org:10.3390/cancers12071754
14. Hou, J., Li, X. & Xie, K.-P. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Molecular Cancer 20, 34 (2021). https://doi.org:10.1186/s12943-021-01309-7
15. Kalubowilage, M. et al. Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors. Nanomedicine 14, 1823-1832 (2018). https://doi.org:10.1016/j.nano.2018.04.020
16. Wang, H. et al. Nanoplatforms for highly sensitive fluorescence detection of cancer-related proteases. Photochem Photobiol Sci 13, 231-240 (2014). https://doi.org:10.1039/c3pp50260k
17. Udukala, D. N. et al. Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection. Beilstein J Nanotechnol 7, 364-373 (2016).
https://doi.org:10.3762/bjnano.7.33
18. Malalasekera, A. P. et al. A nanobiosensor for the detection of arginase activity. Nanomedicine 13, 383-390 (2017). https://doi.org:10.1016/j.nano.2016.08.014
19. Udukala, D. et al. Early detection of non-small cell lung cancer in liquid biopsies by ultrasensitive protease activity analysis. Journal of Cancer Metastasis and Treatment 2020, 25-38 (2020).
20. Covarrubias-Zambrano, O. et al. Optical biosensing of markers of mucosal inflammation. Nanomedicine 40, 102476 (2022). https://doi.org:10.1016/j.nano.2021.102476
21. Bond, J. S. Proteases: History, discovery, and roles in health and disease. J Biol Chem 294, 1643-1651 (2019).
https://doi.org:10.1074/jbc.TM118.004156
22. Kobayashi, H. & Choyke, P. L. Target-Cancer-Cell-Specific Activatable Fluorescence Imaging Probes: Rational Design and in Vivo Applications. Acc. Chem. Res. 44, 83-90 (2011). https://doi.org:10.1021/ar1000633
23. Wang, H. et al. Nanoplatforms for highly sensitive fluorescence detection of cancer-related proteases. Photochem. Photobiol. Sci. 13, 231-240 (2014). https://doi.org:10.1039/c3pp50260k
24. Böttger, R., Hoffmann, R. & Knappe, D. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLoS One 12, e0178943 (2017). https://doi.org:10.1371/journal.pone.0178943
25. Bond, J. S. Proteases: History, discovery, and roles in health and disease. J Biol Chem 294, 1643-1651 (2019).
https://doi.org:10.1074/jbc.TM118.004156
26. Lopez-Otin, C. & Bond, J. S. Proteases: Multifunctional Enzymes in Life and Disease. J Biol Chem 283, 30433-30437 (2008). https://doi.org:10.1074/jbc.R800035200
27. Bossmann, S. H. in Biomaterials for Cancer Therapeutics - Evolution and Innovation (ed Park K.) 233-259 (Elsevier, 2020).
28. Dudani, J. S., Warren, A. D. & Bhatia, S. N. Harnessing Protease Activity to Improve Cancer Care. Annu Rev Canc Biol 2, 353-376 (2018). https://doi.org:10.1146/annurev-cancerbio-030617-050549
29. Mason, S. D. & Joyce, J. A. Proteolytic networks in cancer. Trends Cell Biol 21, 228-237 (2011). https://doi.org:10.1016/j.tcb.2010.12.002
30. Kalubowilage, M. et al. Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors. Nanomed-Nanotechnol 14, 1823-1832 (2018). https://doi.org:10.1016/j.nano.2018.04.020
31. Udukala, D. N. et al. Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection. Beilstein J Nanotech 7, 364-373 (2016). https://doi.org:10.3762/bjnano.7.33
32. Udukala, D. N. et al. Early detection of non-small cell lung cancer in liquid biopsies by ultrasensitive protease activity analysis. J Cancer Metas Treat 6 (2020). https://doi.org:Artn 25 10.20517/2394-4722.2020.45
33. Dempsey, P. W. et al. Description of an activity-based enzyme biosensor for lung cancer detection. Commun Med (Lond) 4, 37 (2024). https://doi.org:10.1038/s43856-024-00461-7